Comparative study between single dose 600 microg and repeated dose of oral misoprostol for treatment of incomplete abortion

Contraception. 2004 Oct;70(4):307-11. doi: 10.1016/j.contraception.2004.04.002.

Abstract

Objective: To evaluate and compare the effectiveness and side effects of two regimens of oral misoprostol, single dose (600 microg) and repeated dose (1200 microg), in the treatment of incomplete abortion.

Methods: A prospective randomized controlled trial was conducted. One-hundred women who had incomplete abortion (gestational age < 20 weeks) and consented to randomization by computer-generated randomization model prior to treatment. A single oral 600-microg dose or repeated oral dose after 4 h (total 1200 microg) was given to the randomized women.

Results: The overall incidence of complete abortion was 86.9%. This incidence was not statistically different between the single-dose and repeated-dose groups (81.6% vs. 92%, p > 0.05). However, there was a significantly decreased incidence of diarrhea (18.4% vs. 40%, p < 0.05) with the use of single-dose treatment. Overall rate of acceptability and tolerable side effects were 88.9% and 97.9%, respectively. These rates were similar in both groups (87.8% vs. 90% and 98% vs. 98%, p > 0.05).

Conclusions: Oral misoprostol may be a practical alternative in the management of incomplete abortion. Oral misoprostol is acceptable and tolerable to women. Single-dose regimen is as effective as repeated-dose regimen, with a reduction in the incidence of diarrhea.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortifacient Agents, Nonsteroidal / administration & dosage*
  • Abortifacient Agents, Nonsteroidal / adverse effects
  • Abortion, Incomplete / drug therapy*
  • Adult
  • Female
  • Gestational Age
  • Humans
  • Misoprostol / administration & dosage*
  • Misoprostol / adverse effects
  • Patient Satisfaction
  • Pregnancy
  • Prospective Studies
  • Treatment Outcome

Substances

  • Abortifacient Agents, Nonsteroidal
  • Misoprostol